LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Abeona Therapeutics Inc

Abeona Therapeutics Inc

Cerrado

5.82 2.65

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

5.6

Máximo

5.92

Métricas clave
By Trading Economics
Ingresos	3.4M -17M
Ventas	3.3M 8.7M
P/B Media del Sector	5.731 49.888
Margen de beneficios	-195.814
Empleados	226

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+238.62% upside

Dividendos
By Dow Jones
Próximas Ganancias	13 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-15M 268M
Apertura anterior	3.17
Cierre anterior	5.82

Abeona Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 nov 2025, 19:31 UTC

Ganancias

Principales Movimientos del Mercado

Abeona Therapeutics Shares Soar on Higher Demand for Zevaskyn

Comparación entre iguales

Cambio de precio

Abeona Therapeutics Inc previsión

Precio Objetivo

By TipRanks

238.62% repunte

Estimación a 12 Meses

Media 19.2 USD 238.62%

Máximo 22 USD

Mínimo 17 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Abeona Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Abeona Therapeutics Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

Beneficio operativo

Acerca de Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.